Drug intelligence / Profile preview

BW-02

Development stage: Unknown
Lead developer: Novartis
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

BW-02 is a small interfering RNA (siRNA) therapeutic developed by Argo Biopharma in collaboration with Novartis. It is currently in Phase II development for the treatment of hypertension. As an siRNA, BW-02 functions by utilizing the RNA interference pathway to selectively suppress the expression of a specific gene, thereby reducing the production of a protein implicated in the pathogenesis of hypertension. This targeted approach aims to address the underlying molecular mechanisms contributing to the disease.

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on BW-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-02.

Explore the full profile